.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,192,938

« Back to Dashboard

Claims for Patent: 7,192,938

Title:Method of treatment using bisphosphonic acid
Abstract:The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof and administering the dose at a period of one two or three consecutive days per month.
Inventor(s): Bauss; Frieder (Neuhofen, DE), Pichler; Bernhard (Ketsch, DE), Turley; Stephen (Bottmingen, CH)
Assignee: Hoffmann-La Roche Inc. (Nutley, NJ)
Application Number:10/998,849
Patent Claims: 1. A method for treating or inhibiting osteoporosis comprising commencing treatment by orally administering to a subject in need of such treatment, a first dose, on a single day, of a pharmaceutical composition comprising from about 100 mg to about 150 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to about 100 mg to about 150 mg of said bisphosphonic acid and continuing said treatment by orally administering, once monthly on a single day, a pharmaceutical composition comprising from about 100 mg to about 150 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is eguivalent to from about 100 mg to about 150 mg of bisphosphonic acid.

2. The method according to claim 1, wherein the pharmaceutical composition comprises about 100 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to about 100 mg of bisphosphonic acid.

3. The method according to claim 1, wherein the pharmaceutical composition comprises about 150 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to about 150 mg of bisphosphonic acid.

4. The method of claim 1, wherein the pharmaceutical composition comprises 100 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to 100 mg of bisphosphonic acid.

5. The method of claim 1 wherein the pharmaceutical composition comprises 150 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to 150 mg of bisphosphonic acid.

6. The method of claim 1 wherein said bisphosphonic acid is risedronic acid or a pharmaceutically acceptable salt thereof.

7. The method of claim 2 wherein said bisphosphonic acid is risedronic acid or a pharmaceutically acceptable salt thereof.

8. The method of claim 3 wherein said bisphosphonic acid is risedronic acid or a pharmaceutically acceptable salt thereof.

9. The method of claim 5 wherein said bisphosphonic acid is risedronic acid or a pharmaceutically acceptable salt thereof.

10. The method of claim 1 wherein said pharmaceutical composition is a solid pharmaceutical composition.

11. The method of claim 3 wherein said pharmaceutical composition is a solid pharmaceutical composition.

12. The method of claim 5 wherein said pharmaceutical composition is a solid pharmaceutical composition.

13. The method of claim 6 wherein said pharmaceutical composition is a solid pharmaceutical composition.

14. The method of claim 8 wherein said pharmaceutical composition is a solid pharmaceutical composition.

15. The method of claim 9 wherein said pharmaceutical composition is a solid pharmaceutical composition.

16. A method for treating or inhibiting osteoporosis consisting of orally administering to a subject in need of such treatment, once monthly, a pharmaceutical composition comprising from about 100 mg to about 150 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to about 100mg to about 150mg of said bisphosphonic acid.

17. The method according to claim 16, wherein the pharmaceutical composition comprises about 100 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to about 100 mg of bisphosphonic acid.

18. The method according to claim 16, wherein the pharmaceutical composition comprises about 150 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to about 150 mg of bisphosphonic acid.

19. The method of claim 16 wherein the pharmaceutical composition comprises 100 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to 100 mg of bisphosphonic acid.

20. The method of claim 16 wherein the pharmaceutical composition comprises 150 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to 150 mg of bisphosphonic acid.

21. The method of claim 16 wherein said bisphosphonic acid is risedronic acid or a pharmaceutically acceptable salt thereof.

22. The method of claim 17 wherein said bisphosphonic acid is risedronic acid or a pharmaceutically acceptable salt thereof.

23. The method of claim 18 wherein said bisphosphonic acid is risedronic acid or a pharmaceutically acceptable salt thereof.

24. The method of claim 20 wherein said bisphosphonic acid is risedronic acid or a pharmaceutically acceptable salt thereof.

25. The method of claim 16 wherein said pharmaceutical composition is a solid pharmaceutical composition.

26. The method of claim 18 wherein said pharmaceutical composition is a solid pharmaceutical composition.

27. The method of claim 20 wherein said pharmaceutical composition is a solid pharmaceutical composition.

28. The method of claim 16 wherein said pharmaceutical composition is a solid pharmaceutical composition.

29. The method of claim 18 wherein said pharmaceutical composition is a solid pharmaceutical composition.

30. The method of claim 20 wherein said pharmaceutical composition is a solid pharmaceutical composition. once monthly on a single day, a pharmaceutical composition comprising from about 100 mg to about 150 mg of bisphosphonic acid acceptable salt thereof that is eguivalent to from about 100 mg to about 150 mg of bisphosphonic acid.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc